Show simple item record

dc.contributor.authorGurwitz, Jerry H.
dc.contributor.authorGo, Alan S.
dc.contributor.authorFortmann, Stephen P.
dc.date2022-08-11T08:08:20.000
dc.date.accessioned2022-08-23T15:51:52Z
dc.date.available2022-08-23T15:51:52Z
dc.date.issued2016-11-15
dc.date.submitted2017-05-10
dc.identifier.citationJAMA. 2016 Nov 15;316(19):1971-1972. doi: 10.1001/jama.2016.15212. <a href="https://doi.org/10.1001/jama.2016.15212">Link to article on publisher's site</a>
dc.identifier.issn0098-7484 (Linking)
dc.identifier.doi10.1001/jama.2016.15212
dc.identifier.pmid27838724
dc.identifier.urihttp://hdl.handle.net/20.500.14038/29009
dc.description.abstractIntroduction: Given the substantially increasing geriatric population, the need for evidence-based strategies to address the medical and societal consequences of these demographic trends has never been greater. In this context, statins for primary prevention of atherosclerotic cardiovascular disease (ASCVD) provide substantial potential social value by improving health and survival. However, using statins for primary prevention in older adults presents a clinical dilemma. Even though compelling evidence exists supporting statins for secondary prevention in individuals older than 75 years with clinical ASCVD, the same cannot be said for primary prevention. In this Viewpoint, we describe existing evidence on the benefits of statins for primary prevention in older adults, uncertainties about risks, and the need for a randomized trial before non–evidence-based prescribing patterns become irreversibly incorporated into practice.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=27838724&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429025/
dc.subjectCardiology
dc.subjectGeriatrics
dc.subjectDyslipidemia
dc.subjectCardiovascular Disease Risk Factors
dc.subjectCardiovascular Diseases
dc.subjectGeriatrics
dc.titleStatins for Primary Prevention in Older Adults: Uncertainty and the Need for More Evidence
dc.typeJournal Article
dc.source.journaltitleJAMA
dc.source.volume316
dc.source.issue19
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/faculty_pubs/1237
dc.identifier.contextkey10144980
html.description.abstract<p>Introduction: Given the substantially increasing geriatric population, the need for evidence-based strategies to address the medical and societal consequences of these demographic trends has never been greater. In this context, statins for primary prevention of atherosclerotic cardiovascular disease (ASCVD) provide substantial potential social value by improving health and survival. However, using statins for primary prevention in older adults presents a clinical dilemma. Even though compelling evidence exists supporting statins for secondary prevention in individuals older than 75 years with clinical ASCVD, the same cannot be said for primary prevention. In this Viewpoint, we describe existing evidence on the benefits of statins for primary prevention in older adults, uncertainties about risks, and the need for a randomized trial before non–evidence-based prescribing patterns become irreversibly incorporated into practice.</p>
dc.identifier.submissionpathfaculty_pubs/1237
dc.contributor.departmentDepartment of Medicine, Division of Geriatric Medicine
dc.contributor.departmentMeyers Primary Care Institute
dc.source.pages1971-1972


This item appears in the following Collection(s)

Show simple item record